Myriad Genetics (MYGN) PT Lowered to $32 at Needham & Company
Tweet Send to a Friend
Needham & Company analyst Stephen Unger lowered the price target on Myriad Genetics (NASDAQ: MYGN) to $32.00 (from $41.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
